Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study

Keyphrases

• 1-year Outcome 100%
• Tricuspid Valve Replacement 100%
• Tricuspid Regurgitation 100%
• Transfemoral 100%
• Transcatheter Tricuspid Valve Replacement 75%
• Cardiac Output 50%
• Stroke Volume 50%
• New York Heart Association Class 50%
• Severe Tricuspid Regurgitation 50%
• Life Sciences 25%
• Heart Failure 25%
• Functional Quality 25%
• Functional Status 25%
• Quality of Life 25%
• Echocardiography 25%
• Sustained Improvement 25%
• Medical Therapy 25%
• Quality of Life Outcomes 25%
• Intervention Studies 25%
• Comorbid 25%
• All-cause Mortality 25%
• Right Heart 25%
• Hospitalization Rate 25%
• 6-minute Walk Distance (6MWD) 25%
• Major Adverse Events 25%
• Reverse Remodeling 25%
• Event Reduction 25%
• High Survival 25%
• Quality of Life Parameters 25%
• Moderate Tricuspid Regurgitation 25%
• Kansas City Cardiomyopathy Questionnaire 25%
• EVOQUE 25%

Medicine and Dentistry

• Tricuspid Valve Replacement 100%
• Tricuspid Insufficiency 100%
• Quality of Life 42%
• New York Heart Association Class 28%
• Heart Output 28%
• Stroke Volume 28%
• Echocardiography 14%
• Functional Status 14%
• Adverse Event 14%
• Combination Therapy 14%
• All Cause Mortality 14%
• Intervention Study 14%
• Congestive Heart Failure 14%
• Tricuspid Valve 14%
• Myocardial Disease 14%
• Arm 14%
• Hemodynamic 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Tricuspid Valve Regurgitation 100%
• Cerebrovascular Accident 28%
• Intervention Study 14%
• Adverse Event 14%
• Congestive Heart Failure 14%
• Functional Status 14%
• All Cause Mortality 14%
• Myocardial Disease 14%
• Combination Therapy 14%